Pharmacodynamics and pharmacokinetics of multiple doses of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2011
At a glance
- Drugs Vorapaxar (Primary)
- Indications Acute coronary syndromes; Arterial thrombosis; Cerebral infarction
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Schering-Plough
- 05 Nov 2010 New trial record.